2009
DOI: 10.1161/circresaha.108.190397
|View full text |Cite
|
Sign up to set email alerts
|

Estrogen Attenuates Left Ventricular and Cardiomyocyte Hypertrophy by an Estrogen Receptor–Dependent Pathway That Increases Calcineurin Degradation

Abstract: Left ventricular (LV) hypertrophy commonly develops in response to chronic hypertension and is a significant risk factor for heart failure and death. The serine-threonine phosphatase, calcineurin (CnA), plays a critical role in the development of pathologic hypertrophy. Previous experimental studies in murine models show that estrogen limits pressure overload-induced hypertrophy; our purpose was to explore further the mechanisms underlying this estrogen effect. Wild type, ovariectomized female mice were treate… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

5
95
1
3

Year Published

2012
2012
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 133 publications
(104 citation statements)
references
References 31 publications
5
95
1
3
Order By: Relevance
“…Female TG mice show no changes when compared with female or male NTG hearts. Differences in the development of cardiac hypertrophy between sexes have been previously noted (20,32). Thus, the increase in cardiomyocyte area and left ventricular hypertrophy with no change in heart weight to body weight ratio or female cardiac enlargement demonstrates the moderate nature of this hypertrophic phenotype.…”
Section: Resultsmentioning
confidence: 69%
See 1 more Smart Citation
“…Female TG mice show no changes when compared with female or male NTG hearts. Differences in the development of cardiac hypertrophy between sexes have been previously noted (20,32). Thus, the increase in cardiomyocyte area and left ventricular hypertrophy with no change in heart weight to body weight ratio or female cardiac enlargement demonstrates the moderate nature of this hypertrophic phenotype.…”
Section: Resultsmentioning
confidence: 69%
“…These TG hearts show no changes in functional parameters when investigated by echocardiography, myofilament Ca 2ϩ -tension relations, or in studies of work-performing heart during ␤-adrenergic stimulus. However, these animals do have sex-specific differences in heart morphology likely due to the cardioprotective effects of estrogen that have been described previously (19,20). Male TG mice show a hypertrophic phenotype as measured by echocardiography and supported by cardiomyocyte cross-sectional area measurements, whereas female mice do not.…”
Section: Tropomyosin (Tm)mentioning
confidence: 83%
“…8,32,36 Estrogen increases protein S-nitrosylation, a common posttranslational protein modification, 37 and reduces inflammatory markers 32,38 and afterload-or agonist-induced cardiac hypertrophy via the inhibition of calcineurin hypertrophic transcription factor and mitogen-activated protein kinase signaling pathways. 39 Estrogen also improves endothelial and myocardial function after ischemia by an antiapoptotic and pro-survival effect on cardiomyocytes, 40,41 endothelial progenitor cell mobilization 42 and mesenchymal stem cell-mediated vascular endothelial growth factor release. 43,44 These rapid effects of estrogen on the action of CF6 were not examined in this study.…”
Section: Discussionmentioning
confidence: 99%
“…However, men also have higher blood pressure at a given age than women (1 ), as well as higher sympathetic nervous system activity (28 ). In addition, sex steroid hormones such as estrogen may attenuate cardiomyocyte and left ventricular hypertrophy (29 ). Accordingly, premenopausal women will commonly have low cardiac mass and hearts without subtle pathologic structural changes.…”
Section: Hs-ctni Reflects Sex-dependent Differences In Cardiovascularmentioning
confidence: 99%